HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effect of varying molar ratios of potassium-magnesium citrate on thiazide-induced hypokalemia and magnesium loss.

Abstract
This study was conducted to compare the value of an older formulation of potassium-magnesium citrate (K4MgCit2) with newer formulations (K3MgHCit2 and K5MgCit2Cl) with respect to the correction of thiazide-induced hypokalemia and magnesium loss, alkalinizing effect, and citraturic action. Sixty-two healthy volunteers first took hydrochlorothiazide 50 mg/day. After 3 weeks of thiazide treatment (or earlier if hypokalemia developed), they were randomized to take one of three drugs for 3 weeks while continuing thiazide: K4MgCit2 (49 mEq K, 25 mEq Mg, and 74 mEq citrate/day), K3MgHCit2 (49 mEq K, 33 mEq Mg, and 98 mEq citrate/day), and K5MgCit2Cl (49 mEq K, 20 mEq Mg, 10 mEq Cl and 59 mEq citrate/day). Outcome measures were changes in serum potassium and magnesium, and urinary potassium, magnesium, pH, and citrate. The three drugs were equally effective in correcting thiazide-induced hypokalemia. K3MgHCit2 and K4MgCit2 produced a small but significant increase in serum magnesium concentration, whereas K5MgCit2Cl did not. Although all three supplements significantly increased urinary pH and citrate, these effects were more marked with K3MgHCit2 and K4MgCit2 than with K5MgCit2. All three supplements were generally well tolerated, with the lowest side effect profile obtained with K4MgCit2. The new formulation of K3MgHCit2 exerts similar correction of thiazide-induced hypokalemia and magnesium loss, and enhancement of urinary pH and citrate, compared with the older K4MgCit2. However, it is less well tolerated. The new formulation of K5MgCit2Cl does not avert magnesium loss, and has less prominent alkalinizing and citraturic effects than the older preparation.
AuthorsL A Ruml, L A Wuermser, J Poindexter, C Y Pak
JournalJournal of clinical pharmacology (J Clin Pharmacol) Vol. 38 Issue 11 Pg. 1035-41 (Nov 1998) ISSN: 0091-2700 [Print] England
PMID9824785 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Benzothiadiazines
  • Citrates
  • Diuretics
  • Drug Combinations
  • Magnesium Compounds
  • Potassium Compounds
  • Sodium Chloride Symporter Inhibitors
  • Magnesium
  • Potassium
  • potassium-magnesium citrate
Topics
  • Adult
  • Benzothiadiazines
  • Citrates (adverse effects, chemistry, therapeutic use)
  • Diuretics
  • Double-Blind Method
  • Drug Combinations
  • Female
  • Gastrointestinal Diseases (chemically induced)
  • Humans
  • Hypokalemia (chemically induced, drug therapy)
  • Magnesium (blood, metabolism, urine)
  • Magnesium Compounds (adverse effects, chemistry, therapeutic use)
  • Male
  • Middle Aged
  • Potassium (blood, urine)
  • Potassium Compounds (adverse effects, chemistry, therapeutic use)
  • Sodium Chloride Symporter Inhibitors (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: